8-K: Oramed's RoyaltyVest Secures Worldwide License for ZTlido Outside US in Deal with Scilex

Oramed Pharmaceuticals' RoyaltyVest Ltd. has entered into a license agreement with Scilex Pharmaceuticals for the worldwide rights to ZTlido and other lidocaine products outside of the United States.

Summary

• Oramed Pharmaceuticals Inc. has announced that its affiliated company, RoyaltyVest Ltd., has entered into a license agreement with Scilex Pharmaceuticals Inc. for the exclusive worldwide rights (excluding the United States and certain territories) to develop, manufacture, and commercialize ZTlido (lidocaine topical system) 1.8% and SP-103, as well as future lidocaine products.
• RoyaltyVest Ltd. was formed by LidoDev Institutional Investors on January 2, 2025, with Oramed holding 50% of its capital stock.
• Under the agreement, both RoyaltyVest and Scilex will receive 50% of the net revenue generated from the licensed products.
• RoyaltyVest is committed to obtaining regulatory approval for the Lido Product in at least one Major Market Country within 18 months of the effective date (February 22, 2025) and will invest $200,000 annually towards these efforts.
• Scilex has also agreed to appoint RoyaltyVest as its exclusive distributor of the Lido Product in the licensed territory.
• Scilex Holding Company has provided a parent guarantee for Scilex Pharmaceuticals' obligations under the license agreement, which will terminate upon a change of control of Scilex Pharma.

Sentiment

Score: 7

Explanation: The document outlines a strategic licensing agreement that expands market reach and revenue potential. While there are inherent risks, the overall tone is positive due to the potential for growth and collaboration.

Positives

• Oramed gains access to a potentially lucrative market for ZTlido and other lidocaine products outside the US through its affiliation with RoyaltyVest.
• The 50/50 revenue split provides a clear framework for profit sharing between RoyaltyVest and Scilex.
• Scilex's commitment to facilitate introductions to manufacturers and act as exclusive distributor streamlines the initial stages of commercialization for RoyaltyVest.
• The parent guarantee from Scilex Holding Company provides additional security for RoyaltyVest regarding Scilex Pharmaceuticals' obligations.

Negatives

• RoyaltyVest is obligated to invest $200,000 annually towards regulatory approval, representing a financial commitment.
• The agreement excludes the US market, potentially limiting the overall revenue potential for RoyaltyVest.
• The parent guarantee terminates upon a change of control of Scilex Pharma, introducing uncertainty.

Risks

• RoyaltyVest may face challenges in obtaining regulatory approvals for ZTlido and other lidocaine products in international markets.
• Competition from existing pain management products could impact the market share and profitability of ZTlido.
• The termination of the parent guarantee upon a change of control of Scilex Pharma could expose RoyaltyVest to increased financial risk.
• The success of the agreement depends on the continued collaboration and effective communication between RoyaltyVest and Scilex.

Future Outlook

The agreement aims to expand the availability of ZTlido and other lidocaine products to markets outside the US, with RoyaltyVest taking the lead in development, manufacturing, and commercialization in the licensed territories.

Industry Context

This agreement reflects a trend in the pharmaceutical industry of companies seeking to expand their market reach through licensing agreements and strategic partnerships. It allows Scilex to leverage RoyaltyVest's expertise in international markets while focusing on its core US operations.

Comparison to Industry Standards

• Licensing agreements are common in the pharmaceutical industry, particularly for expanding into new geographic markets.
• The 50/50 revenue split is a typical arrangement in such agreements, reflecting the shared risk and reward between the licensor and licensee.
• Similar deals include Teva Pharmaceuticals licensing rights to market products in specific regions, and Sanofi partnering with companies to distribute vaccines in developing countries.
• The $200,000 annual commitment for regulatory approval is relatively modest compared to the overall costs of drug development and commercialization, suggesting a focused approach to market entry.

Stakeholder Impact

• Shareholders of Oramed may benefit from the potential revenue generated by RoyaltyVest's commercialization of ZTlido and other lidocaine products.
• Employees of RoyaltyVest will be involved in the development, manufacturing, and commercialization of the licensed products.
• Patients outside the US may gain access to ZTlido and other lidocaine products for pain management.
• Scilex will benefit from the expanded market reach and revenue sharing arrangement with RoyaltyVest.

Next Steps

• RoyaltyVest will focus on obtaining regulatory approvals for ZTlido and other lidocaine products in key international markets.
• Scilex will facilitate introductions to manufacturers and act as the exclusive distributor of the Lido Product in the licensed territory.
• Both companies will collaborate through joint committees to coordinate development, commercialization, and regulatory activities.

Key Dates